{"pmid":32395951,"title":"[Ethical principles compromised during the COVID-19 pandemic?]","text":["[Ethical principles compromised during the COVID-19 pandemic?]","In the late 1970s, the American bioethicists Tom Beauchamp and James Childress described the four ethical principles that should guide a physician's actions in individual patient care. These principles are: (a) respect for autonomy; (b) doing well (beneficence); (c) not harming (non-maleficence); and (d) justice. In many countries, the global outbreak of SARS-CoV-2 has led to overloaded healthcare systems due to large numbers of COVID-19 patients. In order to provide care to this high volume of patients, far-reaching measures are taken that affect everyone. These measures are not taken from an individual patient's perspective but in the interest of public health; nonetheless, they can directly affect the individual patient's interests. This article examines the extent to which Beauchamp and Childress' ethical principles may be compromised during the COVID-19 pandemic.","Ned Tijdschr Geneeskd","Bakker, Marleen","van de Vathorst, Suzanne","32395951"],"abstract":["In the late 1970s, the American bioethicists Tom Beauchamp and James Childress described the four ethical principles that should guide a physician's actions in individual patient care. These principles are: (a) respect for autonomy; (b) doing well (beneficence); (c) not harming (non-maleficence); and (d) justice. In many countries, the global outbreak of SARS-CoV-2 has led to overloaded healthcare systems due to large numbers of COVID-19 patients. In order to provide care to this high volume of patients, far-reaching measures are taken that affect everyone. These measures are not taken from an individual patient's perspective but in the interest of public health; nonetheless, they can directly affect the individual patient's interests. This article examines the extent to which Beauchamp and Childress' ethical principles may be compromised during the COVID-19 pandemic."],"journal":"Ned Tijdschr Geneeskd","authors":["Bakker, Marleen","van de Vathorst, Suzanne"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395951","source":"PubMed","week":"202020|May 11 - May 17","locations":["American","Beauchamp"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1666627827868368896,"score":9.490897,"similar":[{"pmid":32417870,"title":"Combating COVID-19 Pandemic in Nepal: Ethical Challenges in an Outbreak.","text":["Combating COVID-19 Pandemic in Nepal: Ethical Challenges in an Outbreak.","Pandemic outbreak of COVID-19 is the largest of its kind of this century. All countries throughout the globe are trying their best to contain the disease and eliminate at the earliest. Efforts are continuing to improve the outcome of the infection in terms of minimizing the morbidity and mortality. As a public health strategy every state has the responsibility of protecting the health of the community and such measures includes the preventive measures like social distancing or even lockdown of the state as a whole restricting the movement of the people, diagnostic measures like testing the suspects, contact tracing and isolation of the patients. Treatment of the infected requires decisions in resource constraint situation particularly ICU beds and ventilators. In the meantime, protecting doctors, nurses, other health workers as well as frontline workers need personal protective equipment which is a scarce commodity. While doing so there might be a compromise in the individual autonomy, privacy, confidentiality, and social justice for the beneficence for the larger community. This is an attempt to explore the ethical quandaries in relation to combating COVID-19 in Nepal by relating the issues with the principles of biomedical ethics.","JNMA J Nepal Med Assoc","Shah, Aarati","Aacharya, Ramesh Prasad","32417870"],"abstract":["Pandemic outbreak of COVID-19 is the largest of its kind of this century. All countries throughout the globe are trying their best to contain the disease and eliminate at the earliest. Efforts are continuing to improve the outcome of the infection in terms of minimizing the morbidity and mortality. As a public health strategy every state has the responsibility of protecting the health of the community and such measures includes the preventive measures like social distancing or even lockdown of the state as a whole restricting the movement of the people, diagnostic measures like testing the suspects, contact tracing and isolation of the patients. Treatment of the infected requires decisions in resource constraint situation particularly ICU beds and ventilators. In the meantime, protecting doctors, nurses, other health workers as well as frontline workers need personal protective equipment which is a scarce commodity. While doing so there might be a compromise in the individual autonomy, privacy, confidentiality, and social justice for the beneficence for the larger community. This is an attempt to explore the ethical quandaries in relation to combating COVID-19 in Nepal by relating the issues with the principles of biomedical ethics."],"journal":"JNMA J Nepal Med Assoc","authors":["Shah, Aarati","Aacharya, Ramesh Prasad"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417870","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.31729/jnma.4959","keywords":["covid-19; ethics; public health; strategy."],"locations":["Nepal"],"countries":["Nepal"],"countries_codes":["NPL|Nepal"],"weight":0,"_version_":1667058206832066561,"score":204.92993},{"pmid":32385829,"title":"COVID-19 and off label use of drugs: an ethical viewpoint.","text":["COVID-19 and off label use of drugs: an ethical viewpoint.","BACKGROUND: The COVID-19 outbreak is rapidly spread over the world and kills infected patients. There is no proven medication for its treatment, so, all of the medications used for treatment are considered to be off-label. Off-label uses are not under regulation in the outbreak because there is no specific regulation for this condition. OBJECTIVES: In this short communication we aim at describing two ways of off-label use as clinical practice or investigational use. Further, we will describe the third way of off-label use, we named it pseudo-research and then we will state the most possible ethical challenges of off-label use for better perceptions and responsibility. RESULTS: The WHO considers off-label uses as country-specific. All international regulatory bodies consider off-label prescription as the physician's responsibility and legal by necessitating some requirements. There is no international guideline for regulating investigational off-label uses as clinical practice. CONCLUSION: There are different types of approaches, none of them is comprehensive and conclusive. Furthermore, respecting the four ethical principles necessitates codification and strict regulation of off-label uses either as clinical practice or investigational. Besides, compilation of a special guideline based on ethical principles especially non-maleficence and autonomy for investigational off-label uses in disasters is highly recommended.","Daru","Shojaei, Amirahmad","Salari, Pooneh","32385829"],"abstract":["BACKGROUND: The COVID-19 outbreak is rapidly spread over the world and kills infected patients. There is no proven medication for its treatment, so, all of the medications used for treatment are considered to be off-label. Off-label uses are not under regulation in the outbreak because there is no specific regulation for this condition. OBJECTIVES: In this short communication we aim at describing two ways of off-label use as clinical practice or investigational use. Further, we will describe the third way of off-label use, we named it pseudo-research and then we will state the most possible ethical challenges of off-label use for better perceptions and responsibility. RESULTS: The WHO considers off-label uses as country-specific. All international regulatory bodies consider off-label prescription as the physician's responsibility and legal by necessitating some requirements. There is no international guideline for regulating investigational off-label uses as clinical practice. CONCLUSION: There are different types of approaches, none of them is comprehensive and conclusive. Furthermore, respecting the four ethical principles necessitates codification and strict regulation of off-label uses either as clinical practice or investigational. Besides, compilation of a special guideline based on ethical principles especially non-maleficence and autonomy for investigational off-label uses in disasters is highly recommended."],"journal":"Daru","authors":["Shojaei, Amirahmad","Salari, Pooneh"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385829","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s40199-020-00351-y","keywords":["ethical challenges","investigational off-label uses","off-label prescription","off-label uses"],"weight":0,"_version_":1666340102083706880,"score":170.32591},{"pmid":32250281,"pmcid":"PMC7141248","title":"Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","text":["Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support.","JMIR Public Health Surveill","Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P","32250281"],"abstract":["As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support."],"journal":"JMIR Public Health Surveill","authors":["Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250281","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.2196/18887","keywords":["covid-19","clinical research","ethics","infectious disease","outbreak","pandemic","public health"],"weight":0,"_version_":1666138491030863872,"score":145.76923},{"pmid":32439716,"title":"ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.","text":["ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.","The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.","ESMO Open","de Azambuja, Evandro","Trapani, Dario","Loibl, Sibylle","Delaloge, Suzette","Senkus, Elzbieta","Criscitiello, Carmen","Poortman, Philip","Gnant, Michael","Di Cosimo, Serena","Cortes, Javier","Cardoso, Fatima","Paluch-Shimon, Shani","Curigliano, Giuseppe","32439716"],"abstract":["The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes."],"journal":"ESMO Open","authors":["de Azambuja, Evandro","Trapani, Dario","Loibl, Sibylle","Delaloge, Suzette","Senkus, Elzbieta","Criscitiello, Carmen","Poortman, Philip","Gnant, Michael","Di Cosimo, Serena","Cortes, Javier","Cardoso, Fatima","Paluch-Shimon, Shani","Curigliano, Giuseppe"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439716","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/esmoopen-2020-000793","keywords":["covid-19","esmo adapted recommendations","breast cancer"],"topics":["Prevention"],"weight":1,"_version_":1667523504795287552,"score":136.02997},{"pmid":32392624,"title":"Israel ad hoc COVID 19 committee. Guidelines for care of older persons during a pandemic.","text":["Israel ad hoc COVID 19 committee. Guidelines for care of older persons during a pandemic.","Early on, geriatricians in Israel viewed with increasing alarm the spread of COVID-19. It was clear that this viral disease exhibited a clear predilection for and danger to older persons. Informal contacts began with senior officials from the country's Ministry of Health, the Israel Medical Association and the country's largest Health Fund; this in order to plan an approach to the possible coming storm. A group was formed, comprising three senior geriatricians, a former dean, palliative care specialist and a lawyer/ethicist. The members made every effort to ensure that its recommendations would be practical while at the same time taking into account the tenets of medical ethics. The committee's main task was to think through a workable approach were ICU/ventilator resources be far outstripped by those requiring such care. Recommendations included the approach to older persons both in the community and long term care institutions, a triage instrument and palliative care. Patient autonomy was emphasized with a strong recommendation for people of all ages to update their advance directives or if they did not have any, to quickly draw them up. Considering the value of distributive justice, with respect to triage, a \"soft utilitarian\" approach was advocated with the main criteria being function and co-morbidity. While chronological age was rejected as a sole criterion, in the case of an overwhelming crisis, \"biological age\" would enter into the triage considerations; but only in the case of distinguishing between people with equal non-age related deficits. The guideline emphasized that no matter what, in the spirit of beneficence, anyone who fell ill must receive active palliative care throughout the course of a COVD-19 infection but especially at the end of life. Furthermore, in the spirit of non-maleficence, the very frail, old-old and severely demented would be actively protected from dying on ventilation. This article is protected by copyright. All rights reserved.","J Am Geriatr Soc","Clarfield, A Mark","Dwolatzky, Tzvi","Brill, Shai","Press, Yan","Glick, Shimon","Shvartzman, Pesach","Issi Doron, Israel","32392624"],"abstract":["Early on, geriatricians in Israel viewed with increasing alarm the spread of COVID-19. It was clear that this viral disease exhibited a clear predilection for and danger to older persons. Informal contacts began with senior officials from the country's Ministry of Health, the Israel Medical Association and the country's largest Health Fund; this in order to plan an approach to the possible coming storm. A group was formed, comprising three senior geriatricians, a former dean, palliative care specialist and a lawyer/ethicist. The members made every effort to ensure that its recommendations would be practical while at the same time taking into account the tenets of medical ethics. The committee's main task was to think through a workable approach were ICU/ventilator resources be far outstripped by those requiring such care. Recommendations included the approach to older persons both in the community and long term care institutions, a triage instrument and palliative care. Patient autonomy was emphasized with a strong recommendation for people of all ages to update their advance directives or if they did not have any, to quickly draw them up. Considering the value of distributive justice, with respect to triage, a \"soft utilitarian\" approach was advocated with the main criteria being function and co-morbidity. While chronological age was rejected as a sole criterion, in the case of an overwhelming crisis, \"biological age\" would enter into the triage considerations; but only in the case of distinguishing between people with equal non-age related deficits. The guideline emphasized that no matter what, in the spirit of beneficence, anyone who fell ill must receive active palliative care throughout the course of a COVD-19 infection but especially at the end of life. Furthermore, in the spirit of non-maleficence, the very frail, old-old and severely demented would be actively protected from dying on ventilation. This article is protected by copyright. All rights reserved."],"journal":"J Am Geriatr Soc","authors":["Clarfield, A Mark","Dwolatzky, Tzvi","Brill, Shai","Press, Yan","Glick, Shimon","Shvartzman, Pesach","Issi Doron, Israel"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392624","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/jgs.16554","locations":["Israel","Israel"],"countries":["Israel"],"countries_codes":["ISR|Israel"],"topics":["Prevention"],"weight":1,"_version_":1666528580248535040,"score":132.20074}]}